BRIEF—MilliporeSigma helps accelerate global access to affordable vaccines

MilliporeSigma today announced a partnership with Oxford University's Jenner Institute to develop more robust and scalable vaccine manufacturing processes.

This partnership, as well as plans to develop a vaccine manufacturing facility in Ghana, further the company's commitment to improving global health by making vaccines more affordable and available.

"This collaboration with the Jenner Institute will facilitate access to affordable vaccines while improving the global response to disease outbreaks," said Udit Batra, chief executive of MilliporeSigma, the Life Science business of Germany’s Merck KGaA,

MilliporeSigma building vaccine facility in Ghana

Separately, MilliporeSigma is developing plans for a vaccine manufacturing facility in Ghana, helping to address significant health challenges in a continent that imports 99% of its vaccines.

Working with Ridge Management Solutions and other partners, a recently signed memorandum of understanding between MilliporeSigma and Ridge provides the opportunity for Ghana to become the first country in Sub-Saharan Africa to have a dedicated human vaccine manufacturing factory.